BeiGene's BTK in­hibitor brings in $308M, dri­ves Q2 earn­ings with 46% in­crease from Q1

BeiGene saw huge growth in its BTK in­hibitor Brukin­sa this quar­ter, mark­ing a 139% in­crease from the same time last year and a 46% in­crease from the first quar­ter.

Brukin­sa brought in $308 mil­lion this quar­ter, dri­ving the com­pa­ny’s 82% in­crease in to­tal prod­uct rev­enue — $554 mil­lion — com­pared to this time last year.

The Brukin­sa growth stems from sev­er­al la­bel ex­pan­sions and ap­provals glob­al­ly this year with the launch of the drug for the treat­ment of adult pa­tients with chron­ic lym­pho­cyt­ic leukemia (CLL) in the US, along with ap­provals for ex­pand­ed in­di­ca­tions in Chi­na, Aus­tralia and Cana­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER